[{"id":"ca62bd95-d966-4ef1-89f6-bb6e6f3f98af","acronym":"","url":"https://clinicaltrials.gov/study/NCT06432296","created_at":"2024-05-29T20:34:47.293Z","updated_at":"2024-07-02T16:35:00.222Z","phase":"Phase 3","brief_title":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","source_id_and_acronym":"NCT06432296","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" EPCAM","pipe":"","alterations":" ","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M701"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 03/20/2024","start_date":" 03/20/2024","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2024-05-29"},{"id":"2a88a03e-1a74-4639-bea7-65d7f1196012","acronym":"","url":"https://clinicaltrials.gov/study/NCT05543330","created_at":"2022-09-16T15:56:39.623Z","updated_at":"2024-07-02T16:36:03.810Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","source_id_and_acronym":"NCT05543330","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • M701"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-09-16"},{"id":"07b4179f-e8ed-4410-a9f7-220b1ee391d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501744","created_at":"2021-01-18T21:33:47.040Z","updated_at":"2024-07-02T16:36:42.300Z","phase":"Phase 1","brief_title":"A Study of M701 (EpCAM and CD3) in Malignant Ascites","source_id_and_acronym":"NCT04501744","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" CEACAM5 • MUC16 • AFP • CA 19-9","pipe":" | ","alterations":" CEACAM5 expression • MUC16 expression","tags":["CEACAM5 • MUC16 • AFP • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M701"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2020-08-06"}]